AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20697947
Drug: Conventional integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional integrative medicine
Trial: 10417749
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel 100 microg/g once daily
Trial: 10417749
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel 300 microg/g once daily
Trial: 10417749
Drug: Becaplermin gel
RxNorm normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Becaplermin gel 100 microg/g twice daily
Trial: 10417749
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (sodium carboxymethylcellulose)
Trial: 7496281
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (6 to 16 sessions)
Trial: 2107830
Drug: L‐carnitine supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐carnitine supplemented formula (600 nmol/ml, for 7 days)
Trial: 25533009
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-carnitine supplementation)
Trial: 540521
Drug: Xanthinol nicotinate
RxNorm normalized name: xanthinol
DrugBank: Xanthinol (DB09092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthinol nicotinate (2400 mg daily for 10 weeks)
Trial: 540521
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 tablets daily for 10 weeks)
Trial: 23537458
Drug: sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg
Trial: 29971469
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E vaginal suppository
Trial: 28019010
Drug: Selumetinib 50
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 50 mg (renal impairment study)
Trial: 28019010
Drug: Selumetinib (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (20-50 mg depending on liver dysfunction) (hepatic impairment study)
Trial: 21479690
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia (IA)
Trial: 19817194
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy and horizontal bar exercise
Trial: 17710800
Drug: Enalapril and
RxNorm normalized name: enalapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril and yixin jiangya Capsules
Trial: 15125121
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU of nasal salmon calcitonin daily for three months
Trial: 7512100
Drug: Alprazolam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (6 to 10 mg/day for 43 days)
Trial: 29714449
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MF) for 4 weeks
Trial: 27333970
Drug: AP with
RxNorm normalized name: Unicap with Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP with exercise dosing adjustment (APX)
Trial: 27333970
Drug: AP with
RxNorm normalized name: Unicap with Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP with no exercise dosing adjustment (APN)
Trial: 27333970
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump therapy (SAP)
Trial: 25042878
Drug: Cetuximab +
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab + chemoradiation (63 Gy/35 fractions/7 weeks) with weekly carboplatin + paclitaxel
Trial: 19967577
Drug: No-treatment wait-list
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment wait-list control
Trial: 28732480
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g b.d.)
Trial: 17327307
Drug: Higher-dose oral
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose oral contraceptive (OCP) 35 microg ethinyl estradiol [EE]/2 mg cyproterone acetate
Trial: 17327307
Drug: Low-dose OCP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OCP (20 microg EE/100 microg levonorgestrel + aldactone 50 mg b.d.)
Trial: 16713435
Drug: Simvastatin, 80
RxNorm normalized name: Simvastatin, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin, 80 mg/d
Trial: 8608881
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily after H. pylori eradication
Trial: 8608881
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily before H. pylori eradication
Trial: 7272174
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 60 mg
Trial: 7075499
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 80 mg
Trial: 15374410
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 100 mg
Trial: 2931964
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg t.i.d. for 3 months)
Trial: 2412051
Drug: Ketanserin (subacute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (subacute treatment)
Trial: 23392075
Drug: Bendamustine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine with 500 mL of diluent
Trial: 23392075
Drug: Bendamustine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine with 250 mL of diluent
Trial: 23392075
Drug: Bendamustine concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine concentration ≤0.40 mg/mL
Trial: 23392075
Drug: Bendamustine concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine concentration 0.41-0.60 mg/mL
Trial: 23392075
Drug: Bendamustine concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine concentration >0.60 mg/mL
Trial: 19325050
Drug: Oil-on-top treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-on-top treatment (OT): 4 g of high-oleic-acid rapeseed oil (4.6 ml, 36 kcal) infused after a fat-free liquid meal (LM, 325 ml, 145 kcal)
Trial: 19325050
Drug: Emulsion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion treatment (EM): 4 g of labeled rapeseed oil incorporated into LM (325 ml, 181 kcal); 4.6 ml of saline infused as control
Trial: 17229483
Drug: SPA therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPA therapy (ST)
Trial: 9149172
Drug: Ultrasonic nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic nebulizer therapy with fast inhalation at a respiratory rate of 36 breaths/minute and intermittent vocalization
Trial: 9149172
Drug: Ultrasonic nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic nebulizer therapy with fast inhalation at a respiratory rate of 36 breaths/minute
Trial: 9149172
Drug: Ultrasonic nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic nebulizer therapy with deep and slow inhalation at a respiratory rate of 12 breaths/minute
Trial: 31848062
Drug: Inhaled N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled N-acetylcysteine (NAC) with oral rabeprazole
Trial: 31848062
Drug: Oral rabeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rabeprazole
Trial: 27114389
Drug: Insulin users
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin users in ILI
Trial: 27114389
Drug: Non-insulin users
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin users in ILI
Trial: 22735384
Drug: Dabrafenib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabrafenib (150 mg twice daily, orally)
Trial: 22735384
Drug: Dacarbazine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (1000 mg/m(2) intravenously every 3 weeks)
Trial: 20721651
Drug: Probiotic bacterial
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic bacterial formulation (90 billion CFUs/day)
Trial: 15629973
Drug: Infloran (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infloran (Lactobacillus acidophilus and Bifidobacterium infantis) with breast milk twice daily until discharged
Trial: 11956264
Drug: Sequential biochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential biochemotherapy (CVD + interleukin‐2 + interferon alfa‐2b)
Trial: 11956264
Drug: Chemotherapy (CVD)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CVD)
Trial: 11956264
Drug: Sequential biochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential biochemotherapy
Trial: 9607475
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and urokinase (5,000 U boluses at 12 and 24 hours)
Trial: 2375296
Drug: Fish-oil concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil concentrate (14 g/d, 55% n-3 fatty acids)
Trial: 7285484
Drug: d-amphetamine 15
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 15 mg
Trial: 704653
Drug: d-amphetamine 5-20
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 5-20 mg
Trial: 31382299
Drug: All steroids
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All steroids
Trial: 17116511
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive containing norgestimate (NGM) 180-250 microg and ethinyl estradiol (EE) 35 microg
Trial: 15375469
Drug: Surgical valvular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical valvular treatment associated with isolation of the left atrial posterior wall (treated group)
Trial: 15375469
Drug: Surgical valvular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical valvular treatment (control group)
Trial: 11719726
Drug: Ritonavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (600 mg)
Trial: 29133014
Drug: BrECAPP (brentuximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BrECAPP (brentuximab vedotin 1.8 mg/kg on day 1, etoposide 200 mg/m2 on days 2-4, doxorubicin 35 mg/m2 on day 2, cyclophosphamide 1250 mg/m2 on day 2, procarbazine 100 mg/m2 on days 2-8, and prednisone 40 mg/m2 on days 2-15)
Trial: 29133014
Drug: BrECADD (brentuximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BrECADD (brentuximab vedotin 1.8 mg/kg on day 1, etoposide 150 mg/m2 on days 2-4, doxorubicin 40 mg/m2 on day 2, cyclophosphamide 1250 mg/m2 on day 2, dacarbazine 250 mg/m2 on days 3-4, and dexamethasone 40 mg on days 2-5)
Trial: 25415628
Drug: Low-dose succinylcholine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose succinylcholine (0.5 mg/kg)
Trial: 25415628
Drug: Low-dose rocuronium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rocuronium with sugammadex (0.25 mg/kg and 0.5 mg/kg respectively)
Trial: 17913794
Drug: Trimethoprim (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (160 mg twice daily for 6 days)
Trial: 8836757
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose diltiazem (1 mg)
Trial: 8836757
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose diltiazem (2 or 3 mg)
Trial: 1442572
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of isosorbide dinitrate (ISDN)
Trial: 1442572
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day of isosorbide dinitrate (ISDN)
Trial: 1442572
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of transdermal nitrate
Trial: 1442572
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day of transdermal nitrate
Trial: 30537951
Drug: AOI of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOI of 5 L/min oxygen on the non-ventilated lung immediately at the beginning of OLV
Trial: 24107257
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of a 3% clodronate solution mixed with Tween-20 at a 1:3 ratio
Trial: 24107257
Drug: Conventional implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implant procedure (control side)
Trial: 24107257
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of a 3% clodronate solution
Trial: 14555365
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (enriched stimulus environment, collaborative multidisciplinary interventions, additional yes/no response training)
Trial: 14555365
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (standard hospital environment and interventions)
Trial: 11099571
Drug: Written oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written oral hygiene instruction
Trial: 11099571
Drug: Videotape oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videotape oral hygiene instruction
Trial: 1576626
Drug: Loracarbef 200
RxNorm normalized name: loracarbef 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loracarbef 200 mg once daily for 7 days
Trial: 1576626
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg thrice daily for 7 days
Trial: 4048810
Drug: Oral ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ketoprofen (2 x 50 mg) administered at 7:00 a.m., 1:00 p.m., 7:00 p.m., and 1:00 a.m.
Trial: 4048810
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of ketoprofen (5 mg/kg/day) over 24 hours
Trial: 11943073
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac sodium
Trial: 9522023
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (therapeutic doses)
Trial: 7856290
Drug: CFA/II in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFA/II in biodegradable polymer microspheres (BPM), 1 mg administered via intestinal tube on days 0, 7, 14, and 28.
Trial: 2796243
Drug: Aminophyllin treatment
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophyllin treatment (oral, therapeutic range 4-10 micrograms/ml)
Trial: 2796243
Drug: No aminophyllin
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aminophyllin treatment
Trial: 30988133
Drug: Candesartan (AT1R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (AT1R receptor antagonist)
Trial: 30988133
Drug: C21 (AT2R-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 (AT2R-selective agonist)
Trial: 23830306
Drug: Oral tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tolerance induction
Trial: 23830306
Drug: Triple viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple viral vaccine (MMR)
Trial: 22164960
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid supplementation (0 g/d, 100 g/d, 200 g/d, 300 g/d) with maize silage
Trial: 22164960
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid supplementation (0 g/d, 100 g/d, 200 g/d, 300 g/d) with grass silage
Trial: 22164960
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid supplementation (300 g/d)
Trial: 22164960
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 g/d fumaric acid)
Trial: 22164960
Drug: Fumaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaric acid supplementation (0 g/d, 300 g/d)
Trial: 16776791
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy and physical therapy sessions involving home modifications, problem solving, and training in energy conservation, safe performance, balance, muscle strength, and fall recovery techniques.
Trial: 16776791
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy and physical therapy intervention
Trial: 11562581
Drug: Hypothermic pulsatile
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic pulsatile (n=9, 2.5 L)
Trial: 11562581
Drug: Normothermic pulsatile
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic pulsatile (n=8, 2.5 L/min/m2)
Trial: 11562581
Drug: Normothermic nonpulsatile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic nonpulsatile (n=12, 2.5 L)
Trial: 11562581
Drug: Normothermic nonpulsatile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic nonpulsatile (n=12, 2.8 L)
Trial: 11562581
Drug: Hypothermic nonpulsatile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic nonpulsatile (n=11, 2.5 L)
Trial: 8201064
Drug: Standard procedures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard procedures to maintain pharmacotherapy blinds
Trial: 3047304
Drug: Sulprostone 500
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulprostone 500 mcg 3 times at 4-hour intervals (regimen 1)
Trial: 3047304
Drug: Sulprostone 500
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulprostone 500 mcg every 6 hours for up to 6 injections (regimen 2)
Trial: 28952176
Drug: 2% Cryosim‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Cryosim‐1 cream applied twice daily for seven days
Trial: 28952176
Drug: Placebo-vehicle cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-vehicle cream applied twice daily for seven days
Trial: 28952176
Drug: 2% Cryosim‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Cryosim‐1 cream
Trial: 28952176
Drug: Placebo-vehicle cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-vehicle cream
Trial: 18369591
Drug: ACCM/PALS with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCM/PALS with ScvO(2) goal-directed therapy
Trial: 18369591
Drug: ACCM/PALS without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCM/PALS without ScvO(2) goal-directed therapy
Trial: 12614309
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 200 mg/day
Trial: 12614309
Drug: Valproate (VPA)
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate (VPA) 1250 mg/day
Trial: 10940544
Drug: Self-help group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help group emphasis in treatment
Trial: 7817684
Drug: KH 1060
RxNorm normalized name: KH-176
DrugBank: Sonlicromanol (DB16333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KH 1060 ointment 0.2 microgram/g